Semaglutide linked to lower bone fracture risk

In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared with other anti-obesity medications, according to a study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago.